Metraipolis › archive › dc_4def28370cb8

Efficacy and safety of rivaroxaban versus low-molecular-weight heparin for the prevention of symptomatic in-hospital venous thrombosis following primary total… — Europe PMC PMID:42249325

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42249325
DOI
10.1186/s12891-[numero omesso]-y
License (as archived)
solo-consultazione
Archived
2026-10-31T18:12:33.577Z
SHA-256 of the archived text
3e5175592e65431507355b9080a91869f27c8d595265152c40504708c86094a0
Stable URL of this page
https://metraipolis.com/documento/dc_4def28370cb8

How to cite

Efficacy and safety of rivaroxaban versus low-molecular-weight heparin for the prevention of symptomatic in-hospital venous thrombosis following primary total… — Europe PMC PMID:42249325 — Europe PMC (en), https://europepmc.org/article/MED/42249325 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4def28370cb8 (Metraipolis archive dc_4def28370cb8, sha256 3e5175592e65431507355b9080a91869f27c8d595265152c40504708c86094a0)
BibTeX
@misc{dc4def28370cb8,
  title = {Efficacy and safety of rivaroxaban versus low-molecular-weight heparin for the prevention of symptomatic in-hospital venous thrombosis following primary total… — Europe PMC PMID:42249325},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42249325},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4def28370cb8; sha256 3e5175592e65431507355b9080a91869f27c8d595265152c40504708c86094a0},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42249325. Agents can read the archived copy with the MCP tool read_document.